Prosecution Insights
Last updated: April 19, 2026

Examiner: RAHMAN, MASUDUR

Tech Center 1600 • Art Units: 1623 1631 1633 1634

This examiner grants 70% of resolved cases

Performance Statistics

69.7%
Allow Rate
+9.7% vs TC avg
133
Total Applications
+37.4%
Interview Lift
1512
Avg Prosecution Days
Based on 99 resolved cases, 2023–2026

Rejection Statute Breakdown

4.0%
§101 Eligibility
20.4%
§102 Novelty
44.5%
§103 Obviousness
20.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18034620 OVEREXPRESSION OF INSULIN-LIKE GROWTH FACTOR RECEPTOR MUTANTS TO MODULATE IGF SUPPLEMENTATION Non-Final OA AMGEN INC.
18010857 METHODS AND COMPOSITIONS FOR MODULATING CELLS AND CELLULAR MEMBRANES Non-Final OA FLAGSHIP PIONEERING INNOVATIONS VI, LLC
18283744 METHOD FOR PRODUCING PLURIPOTENT STEM CELL POPULATION Non-Final OA KANEKA CORPORATION
18271294 DRIED CELL SECRETOME-BASED THERAPEUTIC AGENT FOR OSTEOARTHRITIS TREATMENT Non-Final OA SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
17904106 METHODS FOR IMPROVED DELIVERY OF THERAPEUTIC AGENTS Final Rejection William Marsh Rice University
17748983 SPYCATCHER AND SPYTAG: UNIVERSAL IMMUNE RECEPTORS FOR T CELLS Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
17616522 METHODS OF MAKING AND USING LIVER CELLS Final Rejection University Health Network
16669191 COMPOSITIONS AND METHODS FOR TREATING CANCER Non-Final OA University of Virginia Patent Foundation
18341811 HYPOTHERMIC OXYGENATED PERFUSION SOLUTION FOR REPAIRING KIDNEY INJURY AND USE THEREOF Non-Final OA WUHAN UNIVERSITY
17997648 SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS Final Rejection Iovance Biotherapeutics, Inc.
17628509 CHIMERIC CYTOKINE RECEPTOR Non-Final OA AUTOLUS LIMITED
17601684 CELL Non-Final OA AUTOLUS LIMITED
18246250 STERILE ORGANISMS, METHODS OF MAKING, AND METHODS OF USE THEREOF Non-Final OA Brandeis University
17817125 PROCESSES FOR GENERATING SUPERIOR ANTI-TUMOR T-CELL EFFECTOR AND MEMORY CELLS Final Rejection MUSC Foundation for Research Development
18281412 COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES Non-Final OA KOLON LIFE SCIENCE, INC.
18280093 USE OF MESENCHYMAL STEM CELLS OVEREXPRESSING PACER FOR THE TREATMENT OF DISEASES WITH INFLAMMATORY ORIGIN AND/OR COMPONENT Non-Final OA Universidad del Desarrollo
18082857 REGENERATIVE CAR-T CELLS Non-Final OA CREATIVE MEDICAL TECHNOLOGIES, INC.
18331956 METHOD FOR PREPARING TUMOR-DERIVED MICROPARTICLES BY MICROWAVE Non-Final OA Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
17292811 COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER Non-Final OA MEMORIAL SLOAN KETTERING CANCER CENTER
18017107 CLOSED MANUFACTURING PROCESSES FOR LARGE SCALE MANUFACTURING OF PLURIPOTENT STEM CELL DERIVED CELLS Final Rejection NCARDIA B.V.
18016460 METHODS AND COMPOSITIONS FOR TREATING LUNG CONDITIONS Non-Final OA BRAINSTORM CELL THERAPEUTICS LTD.
17599446 EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS Final Rejection TURNSTONE BIOLOGICS CORP.
17788908 Inhibitor of Fertilized Egg Fragmentation Non-Final OA National Center for Child Health and Development
17775801 METHODS AND A KIT TO REPROGRAM SOMATIC CELLS Non-Final OA Atsuo Ochi

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month